Clinical Study On The Expression Of CD56 In Newly Diagnosed Multiple Myeloma Patients And The Efficacy Of Induction Therapy Based On Bortezomib Combined With Lenalidomide

Objective:To analyze the correlation between CD56 expression difference and prognosis in newly diagnosed multiple myeloma patients,and to study the efficacy of bortezomib combined with lenalidomide based induction therapy.Methods:A retrospective analysis was performed on 160 cases of Multiple Myeloma(MM)newly diagnosed in our center from January 2015 to August 2021,which were divided into CD56 positive group(CD56+)and CD56 negative group(CD56-).The clinical features and Overall survival(OS)of the two groups were compared.Among them,a total of 64 newly diagnosed MM patients were treated with Bortezomib combined Lenalidomide based regimen(VRd)for 4 courses.After 4 courses of treatment,efficacy evaluation and OS analysis were conducted,and the difference of efficacy evaluation between the two groups was compared.Results:There are 109 cases(68.1%)in CD56+ group and 51 cases(31.9%)in CD56-group.The levels of β2 microglobulin(β2-MG)and lactate dehydrogenase(LDH)in CD56-group were higher than those in CD56+ group(P=0.041,P=0.032).CD56-group was more likely to have extramedullary lesions(P < 0.001).Patients in CD56+ group had longer OS.CD56-,β2-MG≥8mg/L were independent influencing factors of OS in patients.In 64 patients treated by VRd regimen,there was no significant difference in efficacy assessment between the two groups(P=0.600),and no difference in OS(P=0.962).The decrease of β2-MG and LDH in CD56-group was more obvious than in CD56+ group.Conclusion:1.Newly diagnosed Multiple Myeloma patients with CD56-has higher β2-MG and LDH,are more prone to extramedullary invasion,and have a relatively short OS.CD56-and β2-MG≥8mg/L are independent risk factors for poor prognosis.2.For patients with Myeloma treated with VRd regimen,the therapeutic efficacy of CD56+ group and CD56-group are similar,and there are no significant difference in OS analysis,providing help for more individualized treatment of CD56-patients.